(Q36107187)

12 August 2017

1 reference

title

Tirofiban in acute coronary syndromes (English)

1 reference

12 August 2017

main subject

acute coronary syndrome

1 reference

3

Diego Ardissino

1 reference

12 August 2017

Alberto Menozzi

1

1 reference

12 August 2017

Piera Angelica Merlini

series ordinal

2

1 reference

12 August 2017

publication date

1 March 2005

1 reference

Expert Review of Cardiovascular Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

3

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

193-206

1 reference

Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE)

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Mechanisms of plaque vulnerability and rupture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Integrins: a family of cell surface receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

The TIMI Risk Score for Unstable Angina/Non–ST Elevation MI

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reop

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the M

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Platelet GPIIb-IIIa blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.2.193

21 January 2018

Identifiers

DOI

10.1586/14779072.3.2.193

1 reference

12 August 2017

1 reference